Belinostat (PXD101)

Catalog No.S1085 Synonyms: NSC726630, PX-105684

Belinostat (PXD101) Chemical Structure

Molecular Weight(MW): 318.35

Belinostat (PXD101) is a novel HDAC inhibitor with IC50 of 27 nM in a cell-free assay, with activity demonstrated in cisplatin-resistant tumors.

Size Price Stock Quantity  
In DMSO USD 160 In stock
USD 120 In stock
USD 370 In stock
USD 570 In stock
USD 970 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

5 Customer Reviews

  • Inhibition of LSD1 activity by HDAC inhibitors. a MDA-MB-231 and MDA-MB-468 cells were exposed to indicated HDAC inhibitors for 24 h.

    Breast Cancer Res Treat 2012 131, 777-789. Belinostat (PXD101) purchased from Selleck.

    LSD1 and HDAC inhibitors exhibit synergistic growth inhibition. Cells were simultaneously treated with pargyline or HDAC inhibitors for 48 h.

     

     

    Breast Cancer Res Treat 2010 131(3), 777-789. Belinostat (PXD101) purchased from Selleck.

  • HDACIs That Simultaneously Inhibit HDACs 1 and 6 Showed Greater Antileukemic Activities than HDACIs that Don,t at Cmax Concentrations. THP-1 cells were treated with LBH-589, PXD101, SAHA, VPA, MS-275 and MGCD0103 at Cmax concentrations for 3 h and 24 h, respectively. The cells post 3 h treatments were washed three times with complete medium and divided into two halves. One half of the cells was resuspended in complete media and cultured for up to 24 h to determine the effects of the 3 h treatments on cell proliferation and apoptosis. The other half of the cells was used to prepare whole cell lysates. Whole cell lysates from the 3 h and 24 h treatments were extracted and subjected to Western blots probed by anti-ac-tubulin or-β-actin antibody (panels A&B), or subjected to HDAC1 enzymatic assays post IP as described in the Materials and Methods (Panels C&D). The effects of the 3 h and 24 h HDACI treatments on cell proliferation, as reflected by percent decrease of live cells relative to untreated cells (panel E), and apoptosis (panel F) were determined by flow cytometry analysis as described in the Materials and Methods.

     

     

    PLoS One 2011 6, e17138. Belinostat (PXD101) purchased from Selleck.

    Induction of DNA Damage and Bim Is Critical for HDACI-Induced Apoptosis in Pediatric AML Cells. THP-1 cells were treated with the HDACIs at Cmax concentrations for 3 (panel A) and 24 h (panel B), respectively. Whole cell lysates were extracted and subjected to Western blots probed by anti-p21, -c-Myc, -cH2AX, -Bim, or -β-actin antibody.

     

     

    PLoS One 2011 6, e17138. Belinostat (PXD101) purchased from Selleck.

  • MDA-MB-231 Breast cancer cells were pretreated with Acetyl-H3 and H3, and then treated with the indicated concentrations of  PXD101.

    Dr. Zhang of Tianjin Medical University. Belinostat (PXD101) purchased from Selleck.

Purity & Quality Control

Choose Selective HDAC Inhibitors

Biological Activity

Description Belinostat (PXD101) is a novel HDAC inhibitor with IC50 of 27 nM in a cell-free assay, with activity demonstrated in cisplatin-resistant tumors.
Features Lead compound of Topotarget.
Targets
HDAC [1]
(Cell-free assay)
27 nM
In vitro

Belinostat inhibits the growth of tumor cells (A2780, HCT116, HT29, WIL, CALU-3, MCF7, PC3 and HS852) with IC50 from 0.2-0.66 μM. PD101 shows low activity in A2780/cp70 and 2780AD cells, which are cisplatin and doxorubicin-resistant derivatives of A2780 cells. Belinostat could induce apoptosis through PARP cleavage and acetylation of histones H3/H4. [1] Belinostat inhibits bladder cancer cell growth, especially in 5637 cells, which shows accumulation of G0-G1 phase, decrease in S phase and increase in G2-M phase. [2] The growth inhibitory activity of belinostat on cell lines is not strongly influenced by the multidrug-resistant phenotype, whereas the activity of docetaxel is clearly affected. Belinostat could enhance the growth inhibitory activity of docetaxel or carboplatin in OVCAR-3 and A2780 cells. Belinostat also shows enhanced tubulin acetylation in ovarian cancer cell lines. [3] A recent study shows that Belinostat activates protein kinase A in a TGF-β signaling-dependent mechanism and decreases survivin mRNA. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
NB4 NUDEfFdPS2WubDDWbYFjcWyrdImgRZN{[Xl? MYSwMlIwOsLizszN NY\ZcYZwOjRxNEivO|IhcA>? NXPJR2Vl\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGKxdHigeIlu\SCjbnSg[I9{\SCmZYDlcoRmdnRibXHucoVz NVvxPJMzOjV6NkS3N|I>
HL-60  MmnnR4VtdCCYaXHibYxqfHliQYPzZZk> NHHpRWcxNjJxMtMg{txO M4X2cFI1NzR6L{eyJIg> MkXJ[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIJwfGhidHnt[UBidmRiZH;z[UBl\XCnbnTlcpQhdWGwbnXy MU[yOVg3PDd|Mh?=
NB4 NH;COG5HfW6ldHnvckBCe3OjeR?= NIrpZ5IzyqEQvF2= NYXGRmw2OjRxNEigbC=> MkS5Zoxw[2u|IHPlcIwh[3mlbHWgbY4hWyCyaHHz[S=> MmfBNlU5PjR5M{K=
HL-60  MUTGeY5kfGmxbjDBd5NigQ>? NHvwN5czyqEQvF2= Ml3CNlQwPDhiaB?= M4DkbYJtd2OtczDj[YxtKGO7Y3zlJIlvKFNicHjhd4U> NYHE[m5KOjV6NkS3N|I>
NB4 NX\mZlZiTnWwY4Tpc44hSXO|YYm= NGm2ZWYxNjMEoN88US=> MV:yOE81QC95MjDo MYTlcohidmOnczDSRU1qdmS3Y3XkJIdz[W63bH;jfZRq[yCmaX\m[ZJmdnSrYYTpc44> M{W2NFI2QDZ2N{Oy
HL-60  NF7sVHRHfW6ldHnvckBCe3OjeR?= MUWwMlLDqM7:TR?= NX3RR2dMOjRxNEivO|IhcA>? NGXMSHdmdmijbnPld{BTSS2rbnT1Z4VlKGe{YX71cI9kgXSrYzDkbYZn\XKnboTpZZRqd25? NFTUXm4zPTh4NEezNi=>
PANC-1 MmX6SpVv[3Srb36gRZN{[Xl? NYqzV4hbOTEEoN88US=> NYfjPYo3Oi92L{[gbC=> NUe4SZF5TE2VTx?= NHrKO5FqdmS3Y3XzJGFOWEtiYXP0bZZifGmxbh?= M4rTV|I{PzR|MUm4
PANC-1 M3uxRWNmdGxiVnnhZoltcXS7IFHzd4F6 NXnGOldtOS9zMNMg{txO NILuWo81QCCq MVjEUXNQ Mmm0[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZTDk[ZBmdmSnboSgcYFvdmW{ NVLx[JdLOjN5NEOxPVg>
PANC-1 MXPGeY5kfGmxbjDBd5NigQ>? MVixNOKh|ryP NFvxd3UzNzRiaB?= MUjEUXNQ NGjET|JqdmO{ZXHz[ZMhcW62cnHj[YxtfWyjcjDSU3MhdGW4ZXy= MYmyN|c1OzF7OB?=
H1666 MkPsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlPVO|LDqGh? M3TVcGROW09? NIPXbYZKSzVyPkGwJO69VQ>? NYTvR5FbOjN3MUW3OVI>
H460 M3vFbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlPvO|LDqGh? M4LyO2ROW09? NFrM[FVKSzVyPUCuPFYh|ryP NYLReJRFOjN3MUW3OVI>
H1299 NUDMdVh5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX23NuKhcA>? NFG3Zo9FVVOR MkHWTWM2OD1zLkKg{txO MVSyN|UyPTd3Mh?=
H520 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVrISG5VPzMEoHi= MYXEUXNQ NV7qPZRUUUN3ME2wMlc2KM7:TR?= MYqyN|UyPTd3Mh?=
H1975 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXTmXHhMPzMEoHi= M{fZN2ROW09? M3PJSGlEPTB;MD62PEDPxE1? NGTHW|MzOzVzNUe1Ni=>
H1650 NVfFbXV{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MU[3NuKhcA>? NYHRXGZtTE2VTx?= Ml2zTWM2OD1yLki4JO69VQ>? NIDWdIIzOzVzNUe1Ni=>
H820 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFzOZXo4OsLiaB?= MlTNSG1UVw>? NGLqVpVKSzVyPUCuOEDPxE1? NHP3Um8zOzVzNUe1Ni=>
PC9 MmHzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEnrSXc4OsLiaB?= NEfwN|JFVVOR MmmzTWM2OD1yLkK5JO69VQ>? Mo[xNlM2OTV5NUK=
HCC2279 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX\XNXh1PzMEoHi= MoXSSG1UVw>? MlPzTWM2OD1yLkSg{txO MoXkNlM2OTV5NUK=
HCC827 MknCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYW3NuKhcA>? NGP6eXhFVVOR NELvU2hKSzVyPUCuNlkh|ryP NVqydpB[OjN3MUW3OVI>
HCC2935 M4riUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoDGO|LDqGh? NVKxN4RnTE2VTx?= NWj6U41lUUN3ME2wMlk4KM7:TR?= M4PmTVI{PTF3N{Wy
HCC4006 NYHEXVEyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2WwdVczyqCq NHr0eGhFVVOR NVvES5Y3UUN3ME2wMlQ3KM7:TR?= NEnTepAzOzVzNUe1Ni=>
H460 NYnRdYxPTnWwY4Tpc44hSXO|YYm= NV7Sbmp4PTBywrDuUS=> M4nxZlI1yqCq MYjEUXNQ MlG2[IVkemWjc3XzJGVITlJiZYjwdoV{e2mxbh?= NEPtbWozOzVzNUe1Ni=>
H1650 M2[xWGZ2dmO2aX;uJGF{e2G7 MWi1NFDDqG6P MmPzNlTDqGh? NYnnO3dYTE2VTx?= NVvwU2l4\GWlcnXhd4V{KEWJRmKg[ZhxemW|c3nvci=> MX2yN|UyPTd3Mh?=
PC9 MUPGeY5kfGmxbjDBd5NigQ>? MYG1NFDDqG6P NFXNUnczPMLiaB?= MofWSG1UVw>? MU\k[YNz\WG|ZYOgSWdHWiCneIDy[ZN{cW:w M1X6S|I{PTF3N{Wy
H460 M375SmZ2dmO2aX;uJGF{e2G7 MXSwMlUwOS9{IN88US=> NIr6TIQ1KGh? NGf4OYRFVVOR NXPmXFdMcW6qaXLpeJMhfGinIHzleoVteyCxZjDBb5QhMHBvQXv0LUBidmRiRVfGVi=> NUnifGd[OjN3MUW3OVI>
H1650 MUHGeY5kfGmxbjDBd5NigQ>? MUSwMlUwOS9{IN88US=> MlrWOEBp NUnab|J4TE2VTx?= NIDxSVhqdmirYnn0d{B1cGVibHX2[Yx{KG:oIFHreEApeC2Da4SpJIFv\CCHR1\S MWSyN|UyPTd3Mh?=
PC9 NF22XlBHfW6ldHnvckBCe3OjeR?= MXKwMlUwOS9{IN88US=> MWO0JIg> MUHEUXNQ MkXjbY5pcWKrdIOgeIhmKGyndnXsd{Bw\iCDa4SgLJAuSWu2KTDhcoQhTUeIUh?= NHrSPVEzOzVzNUe1Ni=>
AsPc1 NUj0THRvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkewOFghcA>? NYLDOIxuTUN3ME2wMlMh|ryP MVuyN|Q4PTZ7NR?=
Panc0327 NGDSOVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX20PEBp NHmyWFZGSzVyPUCuOUDPxE1? NFTsUFEzOzR5NU[5OS=>
MiaPaCa2 MoO1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXm0PEBp NICxN25GSzVyPUCuO{DPxE1? M2O1OlI{PDd3Nkm1
BxPc3 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnTyOFghcA>? NUTRV|BkTUN3ME2xMlAh|ryP MlfWNlM1PzV4OUW=
Panc0403 MkfiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NITWSIs1QCCq NGL2VGVGSzVyPUGuNUDPxE1? NE\0ZlUzOzR5NU[5OS=>
Panc1005 NXSwUHQ1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVy0PEBp NEe1[XJGSzVyPUGuNUDPxE1? NGHoR5QzOzR5NU[5OS=>
PL45 NVjRWWpRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYnvPIM2PDhiaB?= Mn\ySWM2OD1{MD64JO69VQ>? NIHaSY8zOzR5NU[5OS=>
Panc0203 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mlf0OFghcA>? NHvzNYtGSzVyPUKyMlIh|ryP M1n3d|I{PDd3Nkm1
Panc0327 M{jXR2Fxd3C2b4Ppd{BCe3OjeR?= NGnDXmoyKM7:TR?= MoO5NlQhcA>? MlfJbY5lfWOnczDhdI9xfG:|aYO= NHGxUGUzOzR5NU[5OS=>
Panc1005 NX:0bHA1SXCxcITvd4l{KEG|c3H5 Mkf4NUDPxE1? NUPTcFVqOjRiaB?= M17UfIlv\HWlZYOgZZBweHSxc3nz NInXOWUzOzR5NU[5OS=>
Panc0403 MoXqRZBweHSxc3nzJGF{e2G7 MWGxJO69VQ>? NYH3eHZmOjRiaB?= NV;INHltcW6mdXPld{BieG:ydH;zbZM> M3XqSVI{PDd3Nkm1
AsPc1 NH7teGlHfW6ldHnvckBCe3OjeR?= NXPkN5JYOS9zMDFOwG0> Ml63NlQhcA>? Mk\nbY5lfWOnczCg[5Jwf3SqIHHydoV{fGWmIHnuJGczN01? MUKyN|Q4PTZ7NR?=
MiaPaCa2 MnG1SpVv[3Srb36gRZN{[Xl? NWPidpNROS9zMDFOwG0> NF:zNYMzPCCq M1jFc4lv\HWlZYOgJIdzd3e2aDDhdpJme3SnZDDpckBIOi:P M3TYZlI{PDd3Nkm1
T3M4 M2DhTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEj6OWkxNThyMDDuUS=> MXy0PEBp NUKwZnp4cW6qaXLpeJMh[2WubDDwdo9tcW[ncnH0bY9vKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz NYTkUVV5OjJ4OEG2PVg>
AsPC-1 Mon6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWPnU4I3OC16MECgcm0> M1PKO|Q5KGh? NYHC[plMcW6qaXLpeJMh[2WubDDwdo9tcW[ncnH0bY9vKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz MYGyNlY5OTZ7OB?=
Panc-1  M1Xaemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF3WT4oxNThyMDDuUS=> MVu0PEBp Mo\MbY5pcWKrdIOgZ4VtdCCycn;sbYZmemG2aX;uJIlvKGFiZH;z[UBl\XCnbnTlcpQhdWGwbnXy M175O|IzPjhzNkm4
T3M4 MlT2RZBweHSxc3nzJGF{e2G7 NFnpNlUyODBxNUCwM|ExODBibl2= MUG0PEBp NEHXZmRqdmS3Y3XzJIRwe2ViZHXw[Y5l\W62IHHwc5B1d3Orcx?= M2rZXFIzPjhzNkm4
AsPC-1 NWXRVFlFSXCxcITvd4l{KEG|c3H5 NXLEZ|BIOTByL{WwNE8yODByIH7N MVe0PEBp MojHbY5lfWOnczDkc5NmKGSncHXu[IVvfCCjcH;weI9{cXN? M4nGVFIzPjhzNkm4
Panc-1  M1\1bWFxd3C2b4Ppd{BCe3OjeR?= NYq0cY5OOTByL{WwNE8yODByIH7N MVq0PEBp NGmzb5VqdmS3Y3XzJIRwe2ViZHXw[Y5l\W62IHHwc5B1d3Orcx?= NWrvVIVwOjJ4OEG2PVg>
HBL-2 NHvjenpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkXSNlQhcA>? Ml\mTWM2OD1yLkSg{txO M1TkNlIxODZ6MEiw
Jeko-1 NXO1SpZPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3juOVI1KGh? NXTnUlRHUUN3ME2wMlIh|ryP M3PHUVIxODZ6MEiw
Granta-519 NF;2[5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWKyOEBp NI\2V3ZKSzVyPUW2MlMh|ryP M1jPUVIxODZ6MEiw
HCT116 M3W1PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUKybm96PDhiaB?= MWnFR|UxRTBwMkig{txO M3;odVE4OTJ2NUm0
HCT116 NELW[FZHfW6ldHnvckBCe3OjeR?= NWfmeGJ[OC57wrFOwG3DqA>? MnXxNlQhcA>? NFPEfGxld3ewLYLl[5Vt[XS|IGTTJJBzd3SnaX6gcIV3\Wy|IHHmeIVzKDcEoHigbY5kfWKjdHnvci=> MlnVNVcyOjR3OUS=

... Click to View More Cell Line Experimental Data

In vivo Belinostat indicates significant tumor growth delay in A2780 and A2780/cp70 xenograft at a dose of 10mg/kg with no effects on the body weight. [1] Belinostat also induces p21WAF1, HDAC core and cell communication genes in mouse bladder tumors. [2] Belinostat monotherapy induces dose-proportional antitumor effects with TGI of 47% at a dose of 100mg/kg in A2780 xenograft. The combination of Belinostat (100 mg/kg) with carboplatin (40 mg/kg) could delay tumor growth from 18.6 days to 22.5 days. [3] Combining with bortezomib, Belinostat results in great tumor inhibition and gastrointestinal toxicity in mice with bortezomib-resistant UMSCC-11A xenograft. [5]

Protocol

Kinase Assay:[1]
+ Expand

Histone Deacetylase Activity:

Subconfluent cultures are harvested and washed twice in ice cold PBS and pelleted by centrifugation at 200 × g for 5 min. The cell pellet is resuspended in two volumes of lysis buffer [60 mM Tris buffer (pH 7.4) containing 30% glycerol and 450 mM NaCl] and lysed by three freeze (dry ice) thaw (30 °C water bath) cycles. Cell debris is removed by centrifugation at 1.2 × 104 g for 5 min, and the supernatant is stored at −80 °C. Histone H4 peptide (sequence SGRGKGGKGLGKGGAKRHRK corresponding to the 20 NH2-terminal residues) is acetylated by a recombinant protein containing the hypoxanthine-aminopterin-thymidine domain of p300, using [3H]acetyl CoA as a source of acetate. H4 peptide (100 μg) is mixed with hypoxanthine-aminopterin-thymidine buffer (50 mM Tris HCl pH 8.0, 5% glycerol, 50 mM KCl, and 0.1 mM EDTA), 1 mM DTT, 1 mM 4-(2-aminoethyl) benzenesulfonylfluoride, 1 × complete protease inhibitors, 50 μL of purified p300, and 1.85 m [3H]acetyl CoA (4.50Ci/mmol) in a final volume of 300 μL and incubated at 30 °C for 45 min. The p300 protein is removed by incubation with 20 μL of 50% Ni-agaroase beads for 1 hour at 4 °C and centrifugation. The supernatant is applied to a 2 mL Sephadex G15 column, and the flow through is collected. One milliliter of distilled H2O is gently applied, and three drop fractions are collected; this is repeated until 4–5 mL of distilled H2O has been added, and ∼40 fractions are collected. Three microliters of each fraction are diluted in 2 mL of scintillation fluid and counted in a scintillation counter to identify the fractions containing the labeled peptide. These fractions are pooled, and 1 μL of the combined sample is measured to assess the radioactivity in every peptide batch (3-7×103 cpm/μL). For activity assays, the reaction is carried out in a total volume of 150 μL of buffer [60 mM Tris (pH 7.4) containing 30% glycerol] containing 2 μL of cell extract and, where used, 2 μL of belinostat. The reaction is started by the addition of 2 μL of [3H] labeled substrate (acetylated histone H4 peptide corresponding to the 20 NH2-terminal residues). Samples are incubated at 37 °C for 45 min, and the reaction stopped by the addition of HCl and acetic acid (0.72 and 0.12 M final concentrations, respectively). Released [3H]acetate is extracted into 750 μL of ethyl acetate, and samples are centrifuged at 1.2× 104 g for 5 min. The upper phase (600 μL) is transferred to 3 mL of scintillation fluid and counted.
Cell Research:[1]
+ Expand
  • Cell lines: A2780, A2780/cp70, 2780AD, HCT116, HT29, WIL, CALU-3, MCF7, PC3 and HS852
  • Concentrations: 0.016 - 10 μM
  • Incubation Time: 24 hours
  • Method: Tumor cell lines are seeded in 5 mL of medium at a density of 8 × 104 cells/25 cm2 flask and incubated for 48 hours. Cells are exposed to Belinostat (0.016 to 10 μM) for 24 hours. The medium is removed, and 1 mL of trypsin/EDTA is added to each flask. Once the cells have detached, 1 mL of medium is added, the cells are resuspended, and those from the control untreated flask are counted. Cells are diluted and plated into 6-cm Petri dishes (three per flask) at a density of 0.5-2× 103 cells/dish depending on the cell line. Cells from the drug-treated flasks are diluted and plated as for the control flasks. Dishes are incubated for 10–15 days at 37 °C. Cells are washed with PBS, fixed in methanol, and stained with crystal violet, and colonies that contained ≥50 cells counted. Sensitivity is expressed as the IC50 defined as the concentration of belinostat required to reduce the number of colonies to 50% of that of the control untreated cells.
    (Only for Reference)
Animal Research:[1]
+ Expand
  • Animal Models: A2780, A2780/cp70 and HCT116 cells are injected s.c. into the right flank of CD1 nu/nu mice.
  • Formulation: Dissolved in DMSO and then diluted in water to give a final concentration of DMSO of 10%
  • Dosages: ≤40 mg/kg
  • Administration: Administered via i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 64 mg/mL (201.03 mM)
Water <1 mg/mL
Ethanol <1 mg/mL
In vivo 2% DMSO+30% PEG 300+ddH2O 10mg/mL

* 1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 318.35
Formula

C15H14N2O4S

CAS No. 414864-00-9
Storage powder
in solvent
Synonyms NSC726630, PX-105684

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01273155 Recruiting Neoplasms|Lymphomas National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) December 22, 2010 Phase 1
NCT02737046 Recruiting Adult T-cell Leukemia-Lymphoma|ATLL University of Miami November 2016 Phase 2
NCT02875002 Not yet recruiting Relapsed and Refractory Aggressive B- and T-cell Lymphomas|Lymphoma Yale University|Massey Cancer Center|Sidney Kimmel Comprehensive Cancer Center October 2016 Phase 1
NCT02701673 Withdrawn Lymphoma M.D. Anderson Cancer Center June 2016 Phase 1|Phase 2
NCT02679131 Recruiting Relapsed/Refractory Solid Tumors/Hematological Malignancies Spectrum Pharmaceuticals, Inc March 2016 Phase 1
NCT02680795 Recruiting Solid Tumors|Hematological Malignancies Spectrum Pharmaceuticals, Inc March 2016 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

Related HDAC Products

Tags: buy Belinostat (PXD101) | Belinostat (PXD101) supplier | purchase Belinostat (PXD101) | Belinostat (PXD101) cost | Belinostat (PXD101) manufacturer | order Belinostat (PXD101) | Belinostat (PXD101) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID